Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 8.2% – Should You Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) rose 8.2% during mid-day trading on Wednesday . The stock traded as high as $21.75 and last traded at $21.49. Approximately 91,333 shares were traded during trading, a decline of 59% from the average daily volume of 223,354 shares. The stock had previously closed at $19.86.

Analysts Set New Price Targets

Several brokerages recently commented on DNTH. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th. TD Cowen assumed coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. Oppenheimer boosted their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $46.83.

Dianthus Therapeutics Stock Up 15.5 %

The stock’s 50-day moving average price is $22.53 and its 200 day moving average price is $25.13. The firm has a market cap of $678.66 million, a price-to-earnings ratio of -9.18 and a beta of 1.82.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds have recently modified their holdings of the company. MetLife Investment Management LLC raised its stake in shares of Dianthus Therapeutics by 3.1% in the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock valued at $313,000 after purchasing an additional 433 shares in the last quarter. Invesco Ltd. increased its holdings in Dianthus Therapeutics by 7.4% in the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock valued at $251,000 after buying an additional 790 shares during the period. SG Americas Securities LLC raised its stake in shares of Dianthus Therapeutics by 9.2% in the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after buying an additional 814 shares in the last quarter. Barclays PLC raised its stake in shares of Dianthus Therapeutics by 2.6% in the 4th quarter. Barclays PLC now owns 42,766 shares of the company’s stock valued at $933,000 after buying an additional 1,082 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Dianthus Therapeutics by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock worth $3,641,000 after acquiring an additional 1,092 shares during the period. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.